Scarica l'app Stockscreener
203.55
0.16%
-0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Farther Finance Advisors LLC Increases Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Price Over Earnings Overview: AbbVie - Benzinga
AbbVie (NYSE:ABBV) Shares Up 0.1% Following Analyst Upgrade - MarketBeat
Expert Insights: The Promise of Genetic Medicine and AbbVie’s Role in Research - AbbVie
AbbVie and Gedeon Richter partner on neuropsychiatric conditions - The Pharma Letter
AbbVie raises profit forecast as CEO cites business "momentum" - MSN
AbbVie Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
AbbVie Inc. (NYSE:ABBV) Shares Bought by Principal Securities Inc. - MarketBeat
William Blair Estimates AbbVie's FY2024 Earnings (NYSE:ABBV) - MarketBeat
AbbVie and EvolveImmune Therapeutics sign oncology collaboration - Pharmaceutical Technology
Rx Rundown: AbbVie, Biogen, GSK and more - MM+M Online
AbbVie Stock Rises After Earnings Beat, Dividend Hike - MSN
AbbVie and EvolveImmune partner to develop advanced cancer therapies - World Pharmaceutical Frontiers
AbbVie’s Deal for Alzheimer’s Antibody Raises Curtain for Roche News on Wednesday - Barron's
UChicago gets $75M from AbbVie Foundation for new cancer center - The Business Journals
AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
University of Chicago Medicine gets $75 million gift from AbbVie Foundation for new cancer center - CBS News
AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter
Evolveimmune snags another investor, inks $1.4B Abbvie deal - BioWorld Online
AbbVie (NYSE:ABBV) Trading 1.5% Higher After Better-Than-Expected Earnings - MarketBeat
AbbVie partners with EvolveImmune for cancer therapy - Investing.com
AbbVie's multibillion-dollar collaboration targets new cancer therapy candidate - Crain's Chicago Business
AbbVie price target raised to $200 from $195 at UBS - TipRanks
AbbVie (NYSE:ABBV) Hits New 12-Month High on Strong Earnings - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $231.00 - MarketBeat
AbbVie Foundation's $75M gift will put its name on new UChicago cancer hospital - Crain's Chicago Business
BMO increases AbbVie stock target, outperform on upbeat quarterly results - Investing.com
AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call Transcript - Insider Monkey
AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira - BioSpace
AbbVie, EvolveImmune Therapeutics Set Cancer Biotherapeutics Collaboration - MarketWatch
Earnings call: AbbVie raises outlook on strong Q3 performance, Skyrizi and Rinvoq growth - Investing.com India
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-To- License Agreement to Develop Next-Generation Cancer Biotherapeutics - Marketscreener.com
AbbVie Inc. (NYSE:ABBV) Shares Bought by JFS Wealth Advisors LLC - MarketBeat
AbbVie (NYSE:ABBV) Updates Q4 2024 Earnings Guidance - MarketBeat
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs - The Motley Fool
AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and ... - Yahoo Finance
AbbVie reports 12% decline in Q3 2024 net income to $1.56bn - World Pharmaceutical Frontiers
AbbVie Reports Solid Q3 2024 Financial Performance - TipRanks
AbbVie: 3 Positives From The Earnings Report (NYSE:ABBV) - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Short Interest Up 8.9% in October - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat - MSN
Super Micro, Alphabet, AMD, Lilly, Reddit, AbbVie, Qorvo, Garmin, and More Movers - Barron's
AbbVie Earnings: Maintaining Fair Value Estimate as Firm Rapidly Pushes Through Humira Headwind - Morningstar
AbbVie Stock Jumps After Upbeat Q3 Earnings, Revised Guidance: Retail Sentiment Hits One-Year High - Barchart
Reasons behind AbbVie Q3 revenue beat? (ABBV:NYSE) - Seeking Alpha
AbbVie stock soars to all-time high of $199.96 amid robust growth By Investing.com - Investing.com South Africa
Committee Stocks on the Move: Shake Shack, Chipotle, Wingstop, Visa and AbbVie - CNBC
AbbVie (ABBV) Q3 2024 Earnings Call Transcript - Nasdaq
AbbVie stock soars to all-time high of $199.96 amid robust growth - Investing.com Canada
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View - Yahoo Finance
AbbVie 3rd-qtr financials beat expectations - The Pharma Letter
AbbVie (NYSE:ABBV) Stock Price Up 3.2% After Dividend Announcement - MarketBeat
AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq - Reuters
AbbVie Inc. (NYSE:ABBV) Plans Dividend Increase$1.64 Per Share - MarketBeat
Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
AbbVie (NYSE:ABBV) Issues FY24 Earnings Guidance - MarketBeat
ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook - TipRanks
AbbVie says ‘pleased’ with progress advancing product pipeline - TipRanks
AbbVie: Q3 Earnings Snapshot - The Washington Post
0.17%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):